NCT03512275View on ClinicalTrials.gov

A Study of Bermekimab in Patients With Hidradenitis Suppurativa

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 20, 2018

Primary Completion Date

January 14, 2019

Study Completion Date

January 14, 2019

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

Bermekimab Monoclonal Antibody 400 mg

subcutaneous injection

Trial Locations (1)

37215

Tennessee Clinical Research Center, Nashville

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03512275 - A Study of Bermekimab in Patients With Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter